CureVac N.V.
Stock Forecast, Prediction & Price Target
CureVac N.V. Financial Estimates
CureVac N.V. Revenue Estimates
CureVac N.V. EBITDA Estimates
CureVac N.V. Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $102.99M N/A | $67.42M -34.53% | $53.75M -20.26% | Avg: $62.87M Low: $32.13M High: $93.59M avg. 16.95% | Avg: $69.47M Low: $25.01M High: $143.93M avg. 10.49% | Avg: $83.13M Low: $29.93M High: $172.24M avg. 19.66% | Avg: $90.46M Low: $32.57M High: $187.44M avg. 8.82% |
Net Income
% change YoY
| $-411.71M N/A | $-249.02M 39.51% | $-260.16M -4.47% | Avg: $-152.25M Low: $-198.17M High: $-106.33M avg. 41.47% | Avg: $-101.41M Low: $-242.74M High: $-17.04M avg. 33.39% | Avg: $-107.99M Low: $-258.48M High: $-18.14M avg. -6.48% | Avg: $-104.75M Low: $-250.72M High: $-17.60M avg. 2.99% |
EBITDA
% change YoY
| $-386.48M N/A | $-223.10M 42.27% | $-234.09M -4.92% | Avg: $-62.87M Low: $-93.59M High: $-32.13M avg. 73.14% | Avg: $-69.47M Low: $-143.93M High: $-25.01M avg. -10.49% | Avg: $-83.13M Low: $-172.24M High: $-29.93M avg. -19.66% | Avg: $-90.46M Low: $-187.44M High: $-32.57M avg. -8.82% |
EPS
% change YoY
| -$2.21 N/A | -$1.32 40.27% | -$1.18 10.60% | Avg: -$0.69 Low: -$0.9 High: -$0.48 avg. 41.57% | Avg: -$0.46 Low: -$1.1 High: -$0.08 avg. 33.39% | Avg: -$0.49 Low: -$1.17 High: -$0.08 avg. -6.48% | Avg: -$0.47 Low: -$1.14 High: -$0.08 avg. 2.99% |
Operating Expenses
% change YoY
| $277.05M N/A | $134.27M -51.53% | $203.59M 51.62% | Avg: $90.16M Low: $46.09M High: $134.22M avg. -55.71% | Avg: $99.63M Low: $35.87M High: $206.42M avg. 10.49% | Avg: $119.22M Low: $42.92M High: $247.02M avg. 19.66% | Avg: $129.74M Low: $46.71M High: $268.82M avg. 8.82% |
FAQ
What is CureVac N.V. stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 17.84% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -198.17M, average is -152.25M and high is -106.33M.
What is CureVac N.V. stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 13.98% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $32.13M, average is $62.87M and high is $93.59M.
What is CureVac N.V. stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 17.86% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$0.9, average is -$0.69 and high is $-0.48.
What is the best performing analyst?
In the last twelve months analysts have been covering CureVac N.V. stock. The most successful analyst is Eun Yang.